Minimal Residual Disease in Solid Malignancies

计划入组 840 人 · 首次发布于 2025 年 12 月 5 日

Determining Minimal Residual Disease Using ctDNA Deep Sequencing

计划入组 34 人 · 首次发布于 2026 年 6 月 22 日

DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies

计划入组 1,600 人 · 首次发布于 2023 年 10 月 11 日

Blinatumomab(Blincyto)

Rx

liver disease program

siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

CURE RARE DISEASE, INC.

United States

Advancements in Minimal Residual Disease Assessment Transforming Myeloma Treatment

MRD Negativity Predicts Superior Survival in Multiple Myeloma Patients

MRD Negativity as a Surrogate Endpoint for PFS in Multiple Myeloma